Become A Member

  1. Home
  2. January 2018
  3. 1. Hyperuricemia in Patients Taking Anti-Tuberculosis Drugs Including Pyrazinamide for both Category-1 and Category-2 Tuberculosis, in Population of KPK-Pakistan
Article Image
Admin

1. Hyperuricemia in Patients Taking Anti-Tuberculosis Drugs Including Pyrazinamide for both Category-1 and Category-2 Tuberculosis, in Population of KPK-Pakistan

Jamaluddin1, Nizamuddin2, Abid Shah2 and Waheed Iqbal2

ABSTRACT

Objective: To document hyperuricemia in patients taking Anti-Tuberculosis Therapy (ATT) including Pyrazinamide (PZA) in both CAT-1 and CAT-2 Patients.

Study Design: An open labeled & single centered longitudinal study.

Place and Duration of Study: This study was conducted at the Khyber Medical College (KMC) & Khyber Teaching Hospital, Peshawar from December 2016 to May 2017.

Materials and Methods: Sixty patients with pulmonary tuberculosis were enrolled. Patients were assigned into 2groups (30 patients in each group), including group-A as CAT-1 patients, who were taking ATT for the first time and group-B as CAT-2, who presented with recurrent tuberculosis and were put on ATT for the second time. Standard ATT was given to group-A and Streptomycin was added to standard ATT in group-B for the first 02months and uric acid (UA) level was done before the initiation of therapy, at the end of two-month intensive regimen and 02-months after the stopping Pyrazinamide. The primary target was to find out hyperuricemia in both groups.

Results: In CAT-1 patients, uric acid was increased to 6.44 ± 0.91 after two months aggressive regimen, and with discontinuation of pyrazinamide in CAT-1 patients for two month the uric acid falls again to 4.71 ± 0.83. Similarly, in CAT-2 patients, uric acid was increased to 6.64 ± 0.91 with two months therapy which downgrade to 5 ± 1.15 after two months of stopping pyrazinamide. There is significantly increase in uric acid level with two months of ATT in both groups (p-value=0.01). There is 100% recovery in female patient in Cat-1 as compared to Cat-2 female patients (91.6%), similarly 94.77% males improved in Cat-1 as compared to Cat-2 males whose recovery is 86.67%. Conclusion: ATT including PZA can cause significant hyperuricemia, in both CAT-1 and CAT-2 patients. This raised in uric acid level is reversible with discontinuation of PZA, but may persist in some of CAT-2 patients. Key Words: Hyperuricemia, Anti tuberculosis drugs, Pyrazinamide, CAT-1 and CAT-2.

Citation of articles: Jamaluddin, Nizamuddin, Shah A, Iqbal W. Hyperuricemia in patients taking antituberculosis drugs including Pyrazinamide for both Category-1 and Category-2 tuberculosis, in population of

 

KPK-Pakistan. Med Forum 2018;29(1):2-5.